Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCESS2 adapted antibiotherapy versus tetracycline derivative in Hurley stage 2 hidradenitis suppurativa
2023-505818-16-00Phase 3Authorised
- Sponsor
- Institut Pasteur
- Start
- May 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of moxifloxacin, rifampicin, metronidazole, ceftriaxone and lymecycline in hidradenitis suppurativa (HS) (2 arms), sponsored by Institut Pasteur. Primary endpoint: Clinical remission at week 12. Planned start May 2025; status: authorised.
02
Drugs
moxifloxacinrifampicinmetronidazoleceftriaxonelymecycline
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2023-505818-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505818-16-00.